Johnson & Johnson Tops Q2 Estimates

Johnson & Johnson (NYSE:JNJ), a global healthcare leader best known for its pharmaceutical, MedTech, and medical device portfolio, reported earnings for Q2 2025 on Wednesday, July 16, 2025, that topped analysts' consensus estimates. The company exceeded market expectations for both adjusted earnings and revenue, even as some non-GAAP profitability measures dipped from the prior year. Revenue was $23.7 billion, topping the analyst estimate of $22.85 billion, while adjusted EPS came in at $2.77 versus an estimated $2.68. While the company’s operational strengths led to higher sales and the quarter saw progress in innovation and product launches, underlying profit growth slipped as the business faces patent expiries, higher costs, and mix pressures. Overall, the quarter was marked by strong sales momentum, multiple product and regulatory milestones, and a rosier outlook for the full year.Source: Johnson & Johnson. Note: Analyst estimates provided by FactSet. YOY = Year over year. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool